Skip to main content
. Author manuscript; available in PMC: 2017 Sep 28.
Published in final edited form as: Cell Syst. 2016 Sep 28;3(3):302–316.e4. doi: 10.1016/j.cels.2016.09.001

Figure 5. Combinatorial deletion of β-catenin co-dependencies.

Figure 5

(A) Protein levels following single or combined deletion of β-catenin and PIK3CA (top panel) or β-catenin and YAP1 (bottom panel). (B) Calculated and observed proliferation changes following introduction of double sgRNAs. As synergistic GI, we considered GI<-0.5 (red) and GI>0.5 were considered as epistatic (blue). (C) Distribution of GI scores. (D–E) Calculated and observed proliferation changes following introduction of double sgRNAs targeting MED12 and the indicated gene in (D) KRAS mutant cell lines (DLD1 and HCT116) or (E) BRAF mutant cell lines (HT29 and RKO). The observed and expected phenotypes were used to generate a linear regression line. (F) The observed and calculated proliferation changes following combined deletion of MED12 with the indicated genes. (G) Following CRISPR-Cas9 mediated deletion of MED12, YAP1 or a combination of MED12 and YAP1, HT29 cells were treated with trametinib. Cell titer glo (CTG) was used to evaluate cell proliferation 5 days post treatment.